Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia

Injection of cholesterol-free immunoliposomes targeted against apolipoprotein B-100 improves lipid profile in tyloxapol-induced hyperlipidemic mice. Immunoliposomes can interact with serum lipoproteins via lipid exchange between the vesicles, and direct capture of atherogenic lipoproteins via apoB-100 monoclonal antibodies on the liposome surface. Resulting liposome-lipoprotein complexes will be efficiently cleared from serum by liver.